Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1351 to 1379 of 1379 results for patients and public

  1. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development

  3. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

    In development [GID-TA10893] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  4. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: 07 August 2024

    Technology appraisal guidance
    In development

  6. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development [GID-TA11281] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    Awaiting development [GID-IPG10392] Expected publication date: 05 February 2025

    Interventional procedures guidance
    Awaiting development

  8. Transperineal laser ablation (TPLA) for treating lower urinary tract symptoms of benign prostatic hyperplasia using a ultra-micro invasive approach.

    Awaiting development [GID-IPG10268] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  9. Electrically stimulated intravesical therapy for Interstitial Cystitis

    Awaiting development [GID-IPG10362] Expected publication date: 29 January 2025

    Interventional procedures guidance
    Awaiting development

  10. Relugolix for treating hormone-sensitive prostate cancer [ID6187]

    In development [GID-TA11141] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux disease

    Awaiting development [GID-IPG10345] Expected publication date: 17 April 2025

    Interventional procedures guidance
    Awaiting development

  12. Caval valve implantation for tricuspid regurgitation

    Awaiting development [GID-IPG10344] Expected publication date: 21 August 2024

    Interventional procedures guidance
    Awaiting development

  13. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development [GID-TA11373] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]

    Awaiting development [GID-TA11565] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  16. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

    In development [GID-TA11391] Expected publication date: 23 October 2024

    Technology appraisal guidance
    In development

  17. Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209

    In development [GID-TA11184] Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Awaiting development [GID-TA11486] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]

    In development [GID-TA10985] Expected publication date: 12 June 2024

    Technology appraisal guidance
    In development

  20. Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]

    In development [GID-TA11371] Expected publication date: 11 September 2024

    Technology appraisal guidance
    In development

  21. Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

    In development [GID-TA11246] Expected publication date: TBC

    Technology appraisal guidance
    In development

  22. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development [GID-TA11500] Expected publication date: TBC

    Technology appraisal guidance
    In development

  23. Nemolizumab for treating prurigo nodularis in adults ID6451

    In development [GID-TA11566] Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessment

    In development [GID-HTE10027] Expected publication date: 05 December 2024

    Health technology evaluations
    In development

  25. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]

    In development [GID-TA11349] Expected publication date: 10 July 2024

    Technology appraisal guidance
    In development

  26. Phrenic nerve pacing for congenital central hypoventilation syndrome

    Awaiting development [GID-IPG10317] Expected publication date: 21 August 2024

    Interventional procedures guidance
    Awaiting development

  27. Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury

    Awaiting development [GID-IPG10367] Expected publication date: 21 August 2024

    Interventional procedures guidance
    Awaiting development

  28. Compression products for wound care

    Awaiting development [GID-HTE10048] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  29. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development [GID-TA10832] Expected publication date: 18 September 2024

    Technology appraisal guidance
    In development